Generic medications in the Lebanese community: understanding and public perception

Genéricos/Investigación | Posted 23/01/2024 post-comment0 Post your comment

A study conducted by Hatem G and Itani R et al. found that factors such as regulatory standards and quality assurance can influence people’s perception of generic drugs. This research involved 385 patients recruited from six public healthcare centers in Lebanon. Like in many countries, the regulatory authority in Lebanon ensures that generic drugs meet the same standards as brand-name drugs.

70 MD002162

Misconceptions about generic drugs can contribute to a lack of knowledge, as reflected in the study’s findings. More than a third of the individuals believed that generic drugs are inferior in quality or effectiveness and have more side effects than brand-name drugs, despite meeting the same rigorous criteria. Since healthcare providers, including doctors and pharmacists, play a vital role in shaping patient perceptions, participants reported them as their primary source of information regarding generics (55.6% and 38.9%, respectively). This result suggests the need to develop informative brochures and pamphlets in plain language and providing personalized explanations to address individual concerns.  

Cost is a significant factor, and affordability influences preferences, especially for those without comprehensive insurance, as only 22.6% declined locally produced generics. Cultural factors, such as preference for brand names due to perceived quality, also affect the public acceptance since, with approximately 73% of individuals seeking their physician's advice before accepting the pharmacist’s substitution.

In the multivariable analysis, the likelihood of accepting generics substitution was 2.15 times higher among those with higher education levels and 4.44 times higher among those who believed that the generic drug is equally effective as the brand-name counterpart. This underscores the effectiveness of tailored interventions aimed at promoting the use of generic drugs, which can help sustain healthcare systems by controlling expenses and ensuring that resources can be allocated more efficiently to other areas of health care.

After adjusting for socio-demographics, the most significant independent factors predicting the willingness to purchase generic drugs were a higher income and the awareness that brand-name and generic medications contain identical active ingredients with comparable effectiveness.

In Lebanon, public awareness campaigns, education, and regulatory oversight were crucial in building trust in generic medications, particularly during the challenging economic times. Reduced access to healthcare services and medications for some individuals promoted the use of generics, often more affordable, tomaintain access to essential treatments. This was noted for psychotropic drugs and is also expected for other drug classes [2]. Therefore, the authors suggest a higher acceptance of substitution during the current situation. Another study will be performed to assess this progress.

Conflict of interest
The authors of the research paper [1] declared that there were no conflicts of interest.

Abstracted by Georges Hatem, Researcher in the Clinical and Epidemiological Research Laboratory, Faculty of Pharmacy, Lebanese University, Hadath, Lebanon. 

Editor’s comment
Readers interested to learn more about generic medicines are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

A review of generic medicine pricing in Europe

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here.

GaBI Journal Citation Impact
2.2 – CiteScore 2021 (calculated on 5 May 2022)

Submit a manuscript to GaBI Journal

Related articles
Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study

Barriers to generics substitution in the Middle East

Generic drug substitution in Lebanon

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Consulta pública para la modificación de la regulación de biosimilares

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Consulta pública para la modificación de la regulación de biosimilares

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 

References
1. Hatem G, Itani R, Ajrouche R, Abbas N, Farah R, Goossens M, et al. Knowledge, perception and acceptance of generic drugs in the general Lebanese population: A cross-sectional survey among adults. The Journal of Medicine Access. 2023;7:27550834221147789.
2. Rachidi M, Hatem G, Hatem M, Zein S, Rachidi S, Awada S. Impact of the COVID-19 pandemic on the consumption patterns of psychotropic drugs and predictors of limited access to medication. The Journal of Medicine Access. 2023;7:27550834231163706.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010